Study for safety and efficacy of fasting therapy of metabolic syndrome

Phase 1

Completed

• Conditions: Metabolic Syndrome

• Registration Number: ITMCTR1900002845
• Lead Sponsor: Sichuan Hospital of Integrated Chinese and Western Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Meet the Global consensus on Metabolic Syndrome of the International Diabetes Alliance, abdominal obesity (waist circumference >=90cm for men and >=80cm for women);
1. HDL-c (high-density lipoprotein cholesterol) <0.9mmol/L (male) or 1.1mmol/L (female);
2. TG (triglyceride) >1.7mmol/L;
3. SBP (systolic blood pressure) >=130mmHg, or DBP (diastolic blood pressure) >=85mmHg;
4. FPG (fasting blood glucose) 5.6 to 11.1 mmol/L;
5. 9.0% or greater HbA1C; Participants are informed of this study and volunteered to participate in the study.

Exclusion Criteria

1. type 1 DM or special type DM, or GDM; Serious complications of liver, kidney, brain, heart and other important organs and systems;
2. participants with other drug trials within the past 3 months; Antibiotics and microecological preparations were taken within 4 weeks;
3. poor blood glucose control and insulin injection >=30u;
4. secondary hypertension;
5. age <18 years and >=70 years;
6. associated with protein-wasting diseases;
7. diarrhea or other gastrointestinal diseases within the last 4 weeks; Previous history of gastrointestinal surgery.

Study & Design

• Study Type: Observational study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proteomics;the oxdiative stress factors;inflammation factors;body weight;